PT2640842T - Métodos e composições para induzir uma resposta imune a egfrviii - Google Patents

Métodos e composições para induzir uma resposta imune a egfrviii

Info

Publication number
PT2640842T
PT2640842T PT11841347T PT11841347T PT2640842T PT 2640842 T PT2640842 T PT 2640842T PT 11841347 T PT11841347 T PT 11841347T PT 11841347 T PT11841347 T PT 11841347T PT 2640842 T PT2640842 T PT 2640842T
Authority
PT
Portugal
Prior art keywords
egfrviii
inducing
compositions
methods
immune response
Prior art date
Application number
PT11841347T
Other languages
English (en)
Inventor
M Lauer Peter
Bahjat Keith
Original Assignee
Providence Health & Services Oregon D/B/A Providence Portland Medical Center
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Providence Health & Services Oregon D/B/A Providence Portland Medical Center, Aduro Biotech Inc filed Critical Providence Health & Services Oregon D/B/A Providence Portland Medical Center
Publication of PT2640842T publication Critical patent/PT2640842T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT11841347T 2010-11-17 2011-11-17 Métodos e composições para induzir uma resposta imune a egfrviii PT2640842T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17

Publications (1)

Publication Number Publication Date
PT2640842T true PT2640842T (pt) 2018-10-12

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11841347T PT2640842T (pt) 2010-11-17 2011-11-17 Métodos e composições para induzir uma resposta imune a egfrviii

Country Status (16)

Country Link
US (3) US9200057B2 (pt)
EP (1) EP2640842B1 (pt)
JP (1) JP5998370B2 (pt)
CN (1) CN103415620B (pt)
CA (1) CA2818353A1 (pt)
CY (1) CY1120622T1 (pt)
DK (1) DK2640842T3 (pt)
ES (1) ES2684684T3 (pt)
HR (1) HRP20181343T1 (pt)
HU (1) HUE039747T2 (pt)
LT (1) LT2640842T (pt)
PL (1) PL2640842T3 (pt)
PT (1) PT2640842T (pt)
RS (1) RS57630B1 (pt)
SI (1) SI2640842T1 (pt)
WO (1) WO2012068360A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
SG10201610161UA (en) 2012-11-06 2017-01-27 Aduro Biotech Inc Facultatively attenuated bacterial species and methods of preparation and use thereof
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
MY175308A (en) 2013-05-18 2020-06-18 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
KR102359691B1 (ko) * 2014-04-24 2022-02-10 어드박시스, 인크. 재조합 리스테리아 백신 균주 및 그 생산 방법
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
CN107250366A (zh) * 2014-10-14 2017-10-13 宾夕法尼亚大学理事会 重组李斯特菌疫苗菌株及其用于癌症免疫疗法的方法
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
AU2016247894A1 (en) * 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
US10455265B2 (en) * 2015-04-27 2019-10-22 Ericsson Ab Program and device class entitlements in a media platform
EP3302574A4 (en) * 2015-05-26 2018-10-17 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
MX2018000210A (es) * 2015-06-24 2018-06-22 Advaxis Inc Dispositivo y proceso de fabricación de inmunoterapia personalizada basada en vectores de suministro.
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
TW201809274A (zh) * 2016-08-01 2018-03-16 美商艾杜諾生物科技公司 蛋白質表現強化子序列及其用途
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
EP0796277B1 (en) * 1994-11-28 2004-03-24 Thomas Jefferson University Fusion junction type iii mutant egf receptor peptide tumour vaccine
AU6501296A (en) 1995-07-21 1997-02-18 General Hospital Corporation, The Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4545151B2 (ja) 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
BRPI0618050A2 (pt) * 2005-11-02 2011-08-16 Univ Duke uso de peptìdeo egfrviii e vacina antitumor em combinação com outros componentes para o tratamento de tumor
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
EP1991263B8 (en) 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
JP2011523553A (ja) 2008-05-19 2011-08-18 アデュロ バイオテック ＰｒｆＡ＊変異株リステリアを含む組成物およびその使用法
US20120100170A1 (en) * 2008-07-24 2012-04-26 Lauer Peter M Compositions and methods for the treatment of hepatitis c
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII

Also Published As

Publication number Publication date
US20180021420A1 (en) 2018-01-25
US20160074491A1 (en) 2016-03-17
DK2640842T3 (en) 2018-08-13
JP5998370B2 (ja) 2016-09-28
CN103415620A (zh) 2013-11-27
SI2640842T1 (sl) 2018-09-28
EP2640842A1 (en) 2013-09-25
WO2012068360A1 (en) 2012-05-24
US20140037662A1 (en) 2014-02-06
US9200057B2 (en) 2015-12-01
ES2684684T3 (es) 2018-10-04
RS57630B1 (sr) 2018-11-30
JP2014504851A (ja) 2014-02-27
EP2640842B1 (en) 2018-05-30
LT2640842T (lt) 2018-09-10
CN103415620B (zh) 2016-10-12
CY1120622T1 (el) 2019-12-11
EP2640842A4 (en) 2014-04-09
CA2818353A1 (en) 2012-05-24
HUE039747T2 (hu) 2019-02-28
US9775891B2 (en) 2017-10-03
HRP20181343T1 (hr) 2018-10-19
PL2640842T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
HK1256896A1 (zh) 用於實現多重cold-pcr的方法和組合物
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
EP2598120A4 (en) COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
ZA201307919B (en) Composition and method for enhancing an immune response
HK1199694A1 (zh) 益生菌組合物和方法
ZA201402734B (en) Collector compositions and methods of using the same
EP2637691A4 (en) MATERIALS AND METHOD FOR CONTROLLING AN IMMUNE RESPONSE TO AN EPITOP
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2552202A4 (en) METHODS AND COMPOSITIONS FOR WEIGHT LOSS
EP2861719A4 (en) COMPOSITIONS AND METHODS FOR DECREASING AN IMMUNE RESPONSE
GB201113770D0 (en) Novel compositions and uses thereof
EP2424990A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING SPECIFIC IMMUNE RESPONSES OF ANTIGEN
HK1173657A1 (zh) 免疫組合物和方法
HK1206970A1 (en) Antigenic compositions and methods
EP2555788A4 (en) METHOD AND COMPOSITIONS FOR THE PROTECTION AND REGENERATION OF THE HEART
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
EP2742139A4 (en) IMMUNOGENIC COMPOSITIONS AND ASSOCIATED METHODS
IL233873A (en) Methods for soaking up immune tolerance to organ transplants
GB201116340D0 (en) Compositions and methods
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods